Daxor Corporation is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). Daxor Corporation developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all.
Company profile
Ticker
DXR
Exchange
Website
CEO
Michael R. Feldschuh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
3M • Baxter International • Boston Scientific • Stryker • Becton, Dickinson And • Teleflex • Resmed • Haemonetics • Hill-Rom • Nuvasive ...
SEC CIK
Corporate docs
IRS number
132682108
DXR stock data
News
Daxor Announces Cooperative Research And Development Phase II Agreement With The Uniformed Armed Services University For The Development Of A Non-nuclear Blood Volume Analysis Device
27 Jun 22
Daxor Reports Will Participate In National Institutes Of Health Intramural Research Program-Sponsored Study For COVID Utilizing Co.'s Blood Volume Analyzer, No Terms Disclosed
25 May 22
Calendar
2 May 22
19 Aug 22
31 Dec 22
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 23 Jun 22 | Caleb DesRosiers | Stock options Common Stock | Grant | Acquire A | No | No | 13.09 | 4,000 | 52.36K | 4,000 |
| 23 Jun 22 | Edward Feuer | Stock Options COMMON STOCK | Grant | Acquire A | No | No | 13.09 | 2,000 | 26.18K | 2,000 |
| 23 Jun 22 | Joy S. Goudie | STOCK OPTIONS COMMON STOCK | Grant | Acquire A | No | No | 13.09 | 2,000 | 26.18K | 2,000 |
| 23 Jun 22 | Henry D. Cremisi | STOCK OPTION COMMON STOCK | Grant | Acquire A | No | No | 13.09 | 2,000 | 26.18K | 2,000 |
| 23 Jun 22 | James A Lombard | STOCK OPTION COMMON STOCK | Grant | Acquire A | No | No | 13.09 | 2,000 | 26.18K | 2,000 |
Institutional ownership, Q1 2022
1.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 5 |
| Opened positions | 4 |
| Closed positions | 0 |
| Increased positions | 1 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 755K |
| Total shares | 70.83K |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 47.33K | $504K |
| Renaissance Technologies | 22.42K | $239K |
| UBS UBS Group AG - Registered Shares | 855 | $9K |
| MS Morgan Stanley | 175 | $2K |
| Tower Research Capital | 52 | $1K |
| Proequities | 0 | $0 |
Financial reports
N-CSR/A
Certified annual shareholder report (management investment company) (amended)
2 May 22
N-CEN
Annual report (registered investment company)
15 Mar 22
N-CSR
Certified annual shareholder report (management investment company)
28 Feb 22
N-CEN/A
Annual report (registered investment company) (amended)
15 Sep 21
N-CEN/A
Annual report (registered investment company) (amended)
15 Sep 21
N-CSRS
Certified semi-annual shareholder report (management investment company)
30 Aug 21
N-CEN
Annual report (registered investment company)
15 Mar 21
N-CSR
Certified annual shareholder report (management investment company)
25 Feb 21
N-CSRS
Certified semi-annual shareholder report (management investment company)
21 Aug 20
N-CEN
Annual report (registered investment company)
13 Mar 20
Current reports
8-K
Submission of Matters to a Vote of Security Holders
29 Jun 22
8-K
Daxor Corporation Commences Trading on The NASDAQ Capital Market
2 Feb 22
8-K
Departure of Directors or Certain Officers
24 Jan 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Jan 22
8-K
Submission of Matters to a Vote of Security Holders
30 Jun 21
8-K
Other Events
6 May 21
8-K
Breakthrough Patent-pending Tracer Developed for Broad Use
15 Mar 21
8-K
Other Events
5 Oct 20
8-K
Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering
21 Jul 20
8-K
Daxor Announces Prospective Randomized Control Trial at Duke University Medical Center to Guide Volume Treatment In Heart Failure Patients
16 Jul 20
Registration and prospectus
25
Voluntary exchange delisting
1 Feb 22
8-A12B
Registration of securities on exchange
1 Feb 22
S-8
Registration of securities for employees
16 Sep 20
POS EX
Additional exhibits for listing
31 Oct 18
RW
Registration withdrawal request
9 May 13
S-8
Registration of securities for employees
5 Jul 04
S-3
Shelf registration
17 Mar 98
Proxies
N-PX
Annual report of proxy voting record
30 Aug 21
N-PX
Annual report of proxy voting record
31 Aug 20
N-PX
Annual report of proxy voting record
30 Aug 19
DEFR14A
Revised proxy
2 Jun 19
DEF 14A
Definitive proxy
30 May 19
N-PX
Annual report of proxy voting record
10 Jul 18
N-PX/A
Annual report of proxy voting record (amended)
12 Jun 18
Other
CERT
Certification of approval for exchange listing
1 Feb 22
EFFECT
Notice of effectiveness
19 Jul 21
CORRESP
Correspondence with SEC
12 Jul 21
EFFECT
Notice of effectiveness
15 Jul 20
CORRESP
Correspondence with SEC
12 Jul 20
EFFECT
Notice of effectiveness
23 May 19
CORRESP
Correspondence with SEC
19 May 19
CORRESP
Correspondence with SEC
16 May 19
CORRESP
Correspondence with SEC
9 May 19
CORRESP
Correspondence with SEC
9 May 19
Ownership
4
DAXOR / JAMES A LOMBARD ownership change
27 Jun 22
4
DAXOR / Henry D. Cremisi ownership change
27 Jun 22
4
DAXOR / Joy S. Goudie ownership change
27 Jun 22
4
DAXOR / Edward Feuer ownership change
27 Jun 22
4
DAXOR / Caleb DesRosiers ownership change
27 Jun 22
NPORT-P
None (Mar 2022 report)
24 May 22
3
DAXOR / Caleb DesRosiers ownership change
28 Jan 22
NPORT-P
None (Sep 2021 report)
3 Nov 21
4
DAXOR / Edward Feuer ownership change
28 Jun 21
4
DAXOR / Joy S. Goudie ownership change
28 Jun 21
Patents
Utility
Blood volume analysis with volume-aware blood component measures and treatment
21 Dec 21
Methods and systems are presented for analyzing the blood of a living being.
Utility
Remote Blood Volume Monitor
23 Sep 20
Systems and methods are disclosed for providing ongoing monitoring and updating of blood volume status, where the system or method can include guidance in the form of recommendations for treatment actions or alerts about altered patient status.
Utility
Flow-through Quantitative Blood Collection Vial
29 Apr 20
A device is presented for storing, transporting, measuring, and collecting blood, having the properties of a precisely determined volume, the ability to be emptied or filled while connected to a continuous source (such as a supply of a drug, or the bloodstream of a patient), and a geometry suitable for the entire device to be placed in the counting chamber of a detector (such as the counting well of a gamma counter).
Utility
Blood Volume Analyzer with Guidance
29 Apr 20
Systems and methods are provided for analyzing blood of a living being, and for presenting guidance for medical treatment.
Utility
Whole Blood Volume Analyzer
29 Apr 20
Systems and methods are provided for measuring blood volume of a living being.